Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) issued an announcement. Recently, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., the holding subsidiary of the company, was approved by the State Drug Administration for drug registration application for new indications of ruvometinib tablets (trade name: fumainine, project code: FCN-159). The new approved indications are for adult patients with neurofibromatosis type I (NF1) with symptoms and inoperable plexiform neurofibromatosis (PN).

Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) issued an announcement. Recently, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., the holding subsidiary of the company, was approved by the State Drug Administration for drug registration application for new indications of ruvometinib tablets (trade name: fumainine, project code: FCN-159). The new approved indications are for adult patients with neurofibromatosis type I (NF1) with symptoms and inoperable plexiform neurofibromatosis (PN).